Miromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs.
114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs.
Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application.
if it succeeds, the opportunity to buy the stock at these prices will be history.
The Market Cap of MIRO is just 214.74Mil
On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs.
Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application.
if it succeeds, the opportunity to buy the stock at these prices will be history.
The Market Cap of MIRO is just 214.74Mil
On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880